RECURRENT FALLOPIAN TUBE CARCINOMA

This early-stage study tests a drug called talazoparib combined with radiation therapy for people whose gynecologic cancer (like ovarian, uterine, or cervical) has returned. The goal is to find the safest dose and see if the combination can shrink tumors. About 24 participants wi…

This study is for women whose ovarian or endometrial cancer has returned or not gone away and has a specific change in the RAS gene. It compares two treatments: a drug called selumetinib alone versus selumetinib combined with olaparib. The goal is to see if the combination can sh…

This study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRalphaDC) with an immunotherapy drug (pembrolizumab). The goal is to safely boost the immune system to rec…

This study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) works better than bevacizumab alone for recurrent ovarian, fallopian tube, or peritoneal cancer that causes fluid buildup. About 60 adults w…

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy combo (pembrolizumab and bevacizumab) can shrink tumors in people with ovarian cancer that has returned. About 80 adults with recurrent ovarian, fallopian tube, or peritoneal cancer will r…

This early-phase study tests a new treatment for ovarian cancer that has come back or not responded to standard therapy. Doctors take a patient's own immune cells (T cells), train them in a lab to recognize a protein called MUC1 found on cancer cells, and then give them back to t…

This study is testing a new radioactive tracer called [18F]FTT to see if it can make PET/CT scans better at finding solid tumors, including ovarian, breast, and other cancers. About 300 adults with known or suspected tumors will receive the tracer and then have a PET/CT scan. The…

This study tests whether a personalized activity program using a Fitbit can help women with advanced ovarian or endometrial cancer exercise more and improve their quality of life. About 120 participants will either get standard care or the automated program. Researchers will also…

This study screens people with advanced solid tumors to see if their cancer has specific genetic changes. Based on those results, they may be matched to a treatment trial that targets their tumor's unique genetics. The goal is to learn how well these targeted combinations work an…

This study follows 2,000 people who have had ovarian or other solid cancers to understand why some later develop blood cancers. Researchers will look at genetic changes and treatment history to identify risk factors. The goal is to improve monitoring and prevention for cancer sur…